1. Third Quarter Results $0.50 earnings per share on 14 percent revenue growth (9 percent local currency)

2. 2 Forward-looking statements/risk factors In order to take advantage of the safe harbor provisions of the private securities litigation reform act of 1995, you should understand that we will be making forward-looking statements in this conference. These statements involve a number of risks and uncertainties, all of which are set forth in detail in our annual report on form 10-K, subsequent quarterly reports on form 10-Q, and our other SEC filings. We assume no obligation to update any forward-looking statement based on new information, future events or any other reason.

3. 3 Q3 overview n 14% revenue growth over Q3 2002 n 9% revenue growth in local currency n Earnings $0.50 per share - including $0.01 from sale of real estate n Biotechnology - chromatographic media for new processes, hardware for drugs in late-stage clinicals, consumables for commercialized drugs n Life sciences - strength in drug discovery labs n Other bioscience - strength in general lab, US pharmaceutical

4. 4 Americas 44% Europe 39% Asia/Pacific 17% Q3 2003 Q3 revenue percentage by geography, product type and market (in local currencies) Biotechnology 35% Life Science 14% Other Bioscience Applications 51% Q3 2003 Consumables and Services 82% Equipment 18% Q3 2003

5. 5 Q3 revenue growth - by geographic region Americas$ 85$ 807%7% Europe826525%12% Asia/Pacific33319%6% Total U.S. dollar$200$17614%9% % Growth Local $ in millions Q3 2003Q3 2002% Growth Currency

6. 6 Q3 Revenue growth by market Biotechnology $69$5916% Life Science26255% Other Bioscience98945% Total local currency1931789% Foreign Exchange7(2) Total U.S. dollar$200$17614% $ in millions Q3 2003Q3 2002 % Growth

7. 7 Biotechnology: quarterly revenue growth and trends (in local currencies) $ millions Quarterly Growth: Q1 2000 – Q3 2003 Revenues by Quarter: Q1 2000 – Q3 2003 ‘00 ‘01 ‘02 ‘03 ‘00 ‘01 ‘02 ’03

8. 8 Biotechnology: consumable and hardware growth and trends (in local currencies) Revenues by Quarter, Biotech Consumables and Hardware: Q1 2001 – Q3 2003 $ millions $0 $10 $20 $30 $40 $50 $60 $70 $80 Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3 Biotech Consumables Biotech Hardware ’01 ’02 ’03 ’02 ’03 Quarterly Growth, Biotech Consumables and Hardware: Q1 2002 – Q3 2003

9. 9 Pipeline of biologicals - and subset of antibodies - remains very promising Over 2000 biologicals in pipeline or launched 1158 224 342 86 381 Pharmaprojects V5, from PJP Publications, NYC & London, September, 2003 Over 400 therapeutic antibodies in pipeline or launched 48 77 22 20 310

10. 10 Life science: quarterly revenue growth and trends (in local currencies) $ millions Quarterly Growth: Q1 2000 – Q3 2003 Revenues by Quarter: Q1 2000 – Q3 2003 ‘00 ‘01 ‘02 ’03

11. 11 Other bioscience - profitable, cash-generating (in local currencies) $ millions Quarterly Growth: Q1 2000 – Q3 2003 Revenues by Quarter: Q1 2000 – Q3 2003 ‘00 ‘01 ‘02 ’03

12. 12 Actual Dollars (In millions, except EPS) 20032002 Growth Sales$ 200.1$ 175.614% Gross Profit108.598.810% % of Sales54.2%56.3% SG&A60.054.211% % of Sales 30.0%30.9% R&D14.012.98% % of Sales 7.0%7.4% Restructuring and other (0.8) 0.5N/A % of Sales (0.4%) 0.3% Operating income 35.231.1 13% % of Sales17.6%17.7% Net income from continuing operations$ 24.6$ 18.9- EPS - continuing operations$ 0.50$ 0.39- Q3 income statement Quarter ended September 30,

13. 13 Currency added 5 points to growth rate Euro/Dollar, 7/1/03 - 9/30/03 Yen/Dollar, 7/1/03 - 9/30/03

14. 14 Revised guidance for 2003 n Revenue guidance n 12 to 13% projected growth n 4 to 5% in local currency n Revenue growth by market - local currency n Biotechnology: 4 to 5% n Life Sciences: 4 to 5% n Other Bioscience: 4 to 5% n Gross Margins - averaging 55% n SG&A: averaging 31% n R&D: between 7 and 8% n Contribution: approximately 17% n EPS: $1.87 to $1.89 per share